Trials / Terminated
TerminatedNCT05010525
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Shanghai Antengene Corporation Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors
Detailed description
This is A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATG-016 | 48 patients enrolled, orally, each 3 week (21-day) a cycle |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
- First posted
- 2021-08-18
- Last updated
- 2023-03-17
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05010525. Inclusion in this directory is not an endorsement.